Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Primary Renal Cancer (RCC)

NCT02141919 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT02141919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02141919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Primary Renal Cancer (RCC)
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2013
Completion date
June 30, 2026
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal cancers